Posttransplant monomorphic Burkitt’s lymphoma: clinical characteristics and outcome of a multicenter series

S. Bobillo, P. Abrisqueta, B. Sánchez-González, E. Giné, S. Romero, M. Alcoceba, E. González-Barca, S. González de Villambrosía, J. M. Sancho, P. Gómez, L. Bento, J. Montoro, S. Montes, A. López, F. Bosch

Research output: Contribution to journalArticleResearch

2 Citations (Scopus)


© 2018, Springer-Verlag GmbH Germany, part of Springer Nature. Burkitt’s monomorphic posttransplant lymphoproliferative disorder (B-PTLD) is an uncommon subtype of PTLD. Owing to the paucity of this complication, clinical characteristics and outcome has not been fully described. Clinical characteristics and outcomes of 20 patients diagnosed with B-PTLD from 10 transplant centers belonging to the GEL/TAMO group were reviewed. Median time from transplant to B-PTLD was 7.2 years. All the cases fulfill the morphologic and genetic criteria of B-PTLD, whereas Epstein-Barr virus (EBV) was detected in 70% of cases. Patients were treated with different chemotherapy combinations, and three patients received upfront rituximab monotherapy. The great majority of patients receiving CHOP-like regimens attained a complete response (CR) (73%), similar to that obtained with dose-intensive chemotherapy (83% CR). In contrast, patients receiving upfront rituximab monotherapy required subsequent chemotherapy. Two patients (10%) died during treatment due to infection. The median progression-free survival and overall survival (OS) were 16 months and 139 months, respectively. When analyzing variables predicting for OS, we found that patients with bone marrow involvement had an adverse prognosis, with a median OS of 6 months (p = 0.008). In conclusion, B-PTLD is an uncommon complication usually associated with EBV infection and with an aggressive clinical course, particularly in patients with bone marrow involvement. High-dose chemoimmunotherapy obtained similar responses to R-CHOP, suggesting that R-CHOP could be an adequate alternative for these patients. In contrast, rituximab monotherapy does not seem to be effective enough to control the disease.
Original languageEnglish
Pages (from-to)2417-2424
JournalAnnals of Hematology
Publication statusPublished - 1 Dec 2018


  • Burkitt’s lymphoma
  • Posttransplant lymphoproliferative disorders
  • Transplantation


Dive into the research topics of 'Posttransplant monomorphic Burkitt’s lymphoma: clinical characteristics and outcome of a multicenter series'. Together they form a unique fingerprint.

Cite this